The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Filipe Pereira awarded the Eric K. Fernström Prize for Young Researchers

portrait filipe pereira. photo.
"I have been active in the field of cell reprogramming for twenty years and the Fernström Prize is a fantastic way to celebrate this anniversary," says Filipe Pereira, recipient of the Fernström Prize for Young, Successful in Lund. Photo: Tove Smeds.

Filipe Pereira, professor of molecular medicine at Lund University, is awarded this year's Fernström prize for young, exceptionally promising, and successful researchers. He receives the award for his work on reprogramming blood cells and the development of immunotherapies based on this technology.

It was a sheep that determined Filipe Pereira's career choice. He was in high school when he heard about Dolly, one of the world's most extreme examples of cell reprogramming. This sparked Filipe Pereira's curiosity about the human body, and he put aside his plans to study architecture, choosing instead biology and later pursue a doctorate in epigenetics.
Since then, Filipe Pereira's research has taken him around the world, from his home country in Portugal to London, New York and Sweden. Today, he is a professor of molecular medicine at Lund University, and in recent years, his research successes and prestigious research grants have followed one another.

– I am happy and extremely honored to receive this prestigious award. I have been in the field of Cellular Reprogramming for twenty years and the Fernström prize is a fantastic way to celebrate this milestone!

Filipe Pereira has found his niche at the interface of cellular reprogramming and blood cell identity. He has succeeded in converting human skin cells into blood stem cells, which is a first step towards creating fully functional blood stem cells in test tubes. Blood stem cells lose important characteristics when they are cultured, while skin cells are both easily accessible and can be easily expanded in test tubes. Reprogramming skin cells to blood stem cells could potentially provide an unlimited source of cells for transplantation to patients with blood disorders.

Pereira's research also involves reprogramming skin cells into dendritic cells, which are the sentinels of the immune system. They play a key role in orchestrating the immune response by "informing" other immune cells about the threat from foreign substances in the body. In cancer patients dendritic cells may become dysfunctional or excluded from tumors. Therefore, new ways are needed to reprogram other cells into immune cells with the same capacity as the "natural" dendritic cells.

– Through the cloning of Dolly, we learned that the cell nucleus contains all the genetic information needed for the cell to develop into any type of cell. The challenge is knowing which molecules need to be added to alter gene expression and initiate reprogramming.

By using skin cells as the starting cell-type, he managed to identify the three molecules needed to “program” dendritic cells in just nine days. In the next step, he used the same molecules to reprogram cancer cells into dendritic cells. In other words, using the molecules as a trojan horse to "force" cancer cells to develop into immune cells. The reprogrammed cancer cells thereby lose their ability to become tumors, and instead activate the immune system to respond to mutated proteins in the tumor.

– There have been significant advancements in the field of immunotherapy, offering hope to patients that cannot be treated with chemotherapy or radiotherapy. However, as tumors evade immune system detection many patients or tumor types do not respond. Our findings are paving the way for the development of a gene therapy for cancer where the three molecules are delivered directly into tumors in patients eliciting a response independently of the tumor type.


Filipe Pereira, Professor of Molecular Medicine at Lund University and WCMM Fellow at the Wallenberg Centre for Molecular Medicine at Lund University. Pereira is also co-founder of Asgard Therapeutics.
Profile in the Research Portal

Eric K. Fernström Foundation

Each year, the Eric K. Fernström Foundation awards a Nordic prize to a medical researcher from one of the Nordic countries, as well as local prizes, 100 000 SEK, to young successfulresearchers at medical faculties in Sweden. This year's Nordic Prize has a prize sum of half a million SEK. The award ceremonies mark the festive conclusion of Research Day. The Faculty of Medicine at Lund University has collaborated with the Foundation since 1978, when Honorary Doctor of Medicine Eric K. Fernström established the Eric K. Fernström Foundation through a donation.